证券代码：002250 证券简称：联化科技 公告编号：2025-034 联化科技股份有限公司 2024 年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 特别提示： 1、根据《中华人民共和国公司法》（以下简称"《公司法》"）的规定，联化 科技股份有限公司（以下简称"公司"）回购专用证券账户持有的11,459,900股不 享有参与本次权益分派的权利。本次权益分派方案为：以公司现有总股本剔除已 回购股份11,459,900股后的899,873,217股为基数，向全体股东每10股派0.20元（含 税）。 2、根据2024年度权益分派方案，公司本次实际现金分红的总金额=实际参与 分配的总股本×分配比例，即17,997,464.34元=899,873,217股/10×0.20元/股。因 公司回购专用证券账户所持股份不参与现金分红，本次权益分派实施后，根据股 票市值不变原则，实施权益分派前后公司总股本保持不变，现金分红总额分摊到 每一股的比例将减小，因此，本次权益分派实施后除权除息价格计算时，每股现 金红利应以0.0197485元/股计算（每股现金红利 ...

Group 1 - The CRO concept sector experienced a decline of 0.53%, ranking among the top declines in concept sectors, with leading decliners including Lianhua Technology, Shengnuo Biology, and Meinuo Pharma [1][2] - Among the 24 stocks that rose, Sichuan Shuangma, Hanyu Pharmaceutical, and Meihao Medical had the highest increases of 3.14%, 1.98%, and 1.75% respectively [1][4] - The CRO concept sector saw a net outflow of 863 million yuan from major funds, with 47 stocks experiencing net outflows, and five stocks seeing outflows exceeding 30 million yuan [2][3] Group 2 - Lianhua Technology had the largest net outflow of major funds at 436 million yuan, followed by Ruizhi Pharmaceutical, WuXi AppTec, and Meinuo Pharma with outflows of 85 million yuan, 75 million yuan, and 48 million yuan respectively [2][3] - The stocks with the highest net inflows included Hanyu Pharmaceutical, Kailai Ying, and Sichuan Shuangma, with inflows of 37 million yuan, 17 million yuan, and 11 million yuan respectively [2][4] - The trading volume for Lianhua Technology was notably high at 21.98%, indicating significant trading activity despite the decline [3]

Core Viewpoint - Lianhua Technology experienced a significant drop in stock price, reaching the daily limit down, with a trading volume of 2.335 billion yuan and a turnover rate of 20.81% [2] Trading Activity - The stock was listed on the Dragon and Tiger list due to a daily decline of 10.03%, with net purchases from the Shenzhen Stock Connect amounting to 8.8277 million yuan and net sales from brokerage seats totaling 1.52 billion yuan [2] - The top five brokerage seats accounted for a total trading volume of 379 million yuan, with buying transactions of 118 million yuan and selling transactions of 261 million yuan, resulting in a net selling of 143 million yuan [2] - The largest buying brokerage was the Shenzhen Stock Connect, with a buying amount of 31.1602 million yuan and a selling amount of 22.3325 million yuan, leading to a net purchase of 8.8277 million yuan [3] Fund Flow - The stock saw a net outflow of 396 million yuan in main funds today, with a significant outflow of 305 million yuan from large orders and 90.5853 million yuan from big orders [3] - Over the past five days, the main funds experienced a net outflow of 389 million yuan [3] - As of June 17, the margin trading balance for the stock was 784 million yuan, with a financing balance of 782 million yuan and a securities lending balance of 2.1546 million yuan [3] - The financing balance increased by 106 million yuan over the past five days, representing a growth of 15.62%, while the securities lending balance decreased by 16.90 thousand yuan, a decline of 7.27% [3]

Group 1 - The core viewpoint of the article highlights a significant decline in pesticide stocks, with specific companies like Sulih Holdings and Lianhua Technology experiencing a trading halt due to a drop in share prices [1] - The article notes that several other companies in the pesticide sector, including Guangkang Biochemical, Meibang Co., Taihe Co., and Lanfeng Biochemical, saw their stock prices fall by over 5% [1] - Additional companies such as Zhongqi Co. and Hailier also experienced declines, indicating a broader trend of falling stock prices within the pesticide industry [1]

Group 1 - The core viewpoint of the news highlights a significant outflow of capital from the pharmaceutical sector, exceeding 3.1 billion yuan, while other sectors like defense, banking, and electronics saw inflows [1][2]. - The defense and military sector led the capital inflow with 1.574 billion yuan, followed by the banking sector with 972 million yuan and the electronics sector with 682 million yuan [2]. - The pharmaceutical sector experienced the largest capital outflow, with a net outflow of 3.114 billion yuan, followed by the computer sector with 3.048 billion yuan and the machinery equipment sector with 2.052 billion yuan [2]. Group 2 - The top ten stocks with the highest net inflow included Zhongchao Holdings, which saw an inflow of 566 million yuan, and Jiangxi Zhaojin with 304 million yuan [3]. - The stocks with the highest net outflow were led by Rongfa Nuclear Power, which had an outflow of 584 million yuan, followed by Lakala with 491 million yuan [4]. - The net inflow rates for the top stocks varied, with Zhongchao Holdings at 35.85% and Rongfa Nuclear Power at -19.07% [3][4].

Group 1 - The CRO concept sector experienced a decline of 1.65%, ranking among the top declines in the concept sector, with notable declines from companies such as Saint Noble Bio, Meinohua, and Ruizhi Medicine [1][2] - Among the CRO concept stocks, 10 stocks saw price increases, with Wanbang Pharmaceutical, Puni Testing, and Huace Testing leading the gains at 6.96%, 3.37%, and 2.25% respectively [1][2] - The CRO concept sector faced a net outflow of 1.109 billion yuan in main funds, with 48 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2][3] Group 2 - The top net outflow stock was WuXi AppTec, with a net outflow of 337 million yuan, followed by Lianhua Technology, Ruizhi Medicine, and Kailai Ying with net outflows of 136 million yuan, 105 million yuan, and 86 million yuan respectively [2][3] - The stocks with the highest net inflow included Huace Testing, Dongcheng Pharmaceutical, and Jinshi Yao, with net inflows of 29.24 million yuan, 23.51 million yuan, and 15.25 million yuan respectively [2][4] - The overall market sentiment reflected a mixed performance across various concept sectors, with brain-computer interface leading the gains at 6.63% while the CRO concept lagged behind [2][4]

Market Overview - As of June 12, the Shanghai Composite Index closed at 3402.66 points, with a slight increase of 0.34 points, representing a change of 0.01% [1] - The Shenzhen Component Index closed at 10234.33 points, down by 11.69 points, a decrease of 0.11% [1] - The ChiNext Index closed at 2067.15 points, up by 5.29 points, reflecting an increase of 0.26% [1] Trading Activity - A total of 128 A-shares had a turnover rate exceeding 20% on the same day, indicating significant trading activity [1] - Notably, C Haiyang and Zhongke Magnetic had turnover rates exceeding 50%, suggesting a high level of liquidity and interest in these stocks [1] Top Performing Stocks - C Haiyang (603382) had a closing price of 55.97 yuan with a turnover rate of 85.43% and a remarkable increase of 386.70% [1] - Zhongke Magnetic (301141) closed at 68.13 yuan, with a turnover rate of 67.96% and a gain of 3.20% [1] - Yingsite (301622) closed at 97.32 yuan, achieving a turnover rate of 60.53% and a rise of 20.00% [1] - Jiangnan New Materials (603124) closed at 48.20 yuan, with a turnover rate of 57.58% and an increase of 4.83% [1] - Xiongdi Technology (300546) closed at 34.41 yuan, with a turnover rate of 56.64% and a gain of 7.20% [1] Additional Notable Stocks - Kangliyuan (301287) closed at 50.52 yuan, with a turnover rate of 48.58% and a slight decrease of 0.26% [1] - Qingmu Technology (301110) closed at 72.42 yuan, achieving a turnover rate of 46.33% and a rise of 20.00% [1] - Baixinglong (833075) closed at 46.99 yuan, with a turnover rate of 44.54% and an increase of 29.99% [1] - Hengbao Co., Ltd. (002104) closed at 11.82 yuan, with a turnover rate of 44.51% and a gain of 2.34% [1] - Guokang Biochemical (300804) closed at 61.10 yuan, with a turnover rate of 42.76% and a slight increase of 1.08% [1]

Core Viewpoint - The article discusses the recent positive developments in the China-US trade negotiations, highlighting the agreement framework reached between the two countries, which aims to resolve trade tensions and address export restrictions on rare earth minerals and magnets [1]. Group 1: Trade Negotiations - Chinese and US teams have reached a preliminary agreement framework after two days of negotiations, which is expected to be approved by President Trump soon [1]. - The framework adds substantial content to the previously stalled agreement on reducing retaliatory tariffs due to China's export restrictions on key minerals [1]. - The negotiations are characterized as candid, in-depth, and constructive, with both sides exchanging views on trade issues of mutual concern [1][2]. Group 2: Market Reactions - Following the positive news from the trade talks, the A-share market rebounded, with the Shanghai Composite Index rising by 0.52% to surpass 3400 points, despite a decrease in trading volume [2][4]. - The rare earth permanent magnet sector saw significant gains, with several stocks hitting the daily limit up, indicating strong market sentiment [5]. Group 3: Industry Developments - Jinli Permanent Magnet announced it has obtained export licenses for the US, Europe, and Southeast Asia, reflecting the potential for increased international trade in the sector [3]. - The automotive parts sector also experienced notable gains, with several companies committing to shorten payment terms to suppliers, indicating a shift in industry dynamics [6]. Group 4: Financial Insights - The article provides insights into the performance of various indices, noting that over 1700 index funds exist, with the highest dividend yield index being the Hong Kong Stock Connect Mainland Financial Index at 9.37% [7][8]. - A total of 48 indices were identified that meet the criteria of having a fund size of at least 2 billion and a dividend yield above 3%, with 16 indices yielding over 6% [9]. Group 5: Capital Flow - The net inflow of capital into the market was reported at 253.86 billion, with the non-bank financial sector seeing the largest inflow [15]. - Specific stocks such as Jianghuai Automobile and Ningde Times attracted significant attention from investors, indicating strong market interest in these companies [15][18].

Group 1: Market Overview - The total trading volume in the Shanghai and Shenzhen markets reached 1.26 trillion yuan, a decrease of 159.9 billion yuan compared to the previous trading day [2] - Sectors such as rare earth permanent magnets, gaming, automotive parts, and securities saw significant gains, while sectors like controllable nuclear fusion, biological vaccines, communication services, and beverage manufacturing experienced declines [2] Group 2: Notable Stocks - Yiming Pharmaceutical (002826) achieved a limit-up of 9.99%, marking its sixth consecutive trading day of gains, driven by a change in control and diabetes generic drugs [1][2] - Wukuyatu (002878) rose by 9.98%, with a total of five gains over nine days, attributed to digital cultural assets and IP culture [1][2] - Aonlikang (002940) also increased by 9.98%, with seven gains over the past seven days, focusing on innovative drugs and generics [1][2] - Jinying Co. (600232) hit a limit-up of 10.00%, supported by injection molding machines, textile machinery, and lithium batteries, achieving four consecutive gains [1][2] - Chutianlong (003040) saw a limit-up of 10.03%, driven by digital RMB and cross-border payments, with three gains over four days [1][2] Group 3: Institutional Activity - The top three net purchases on the Dragon and Tiger list were from Limin Co. (002734), Chutianlong (003040), and Aonlikang (002940), with net purchases of 166 million yuan, 149 million yuan, and 91.69 million yuan respectively [4] - The top three net sales were from Lianhua Technology (002250), Baili Electric (600468), and Zhi De Co. (603333), with net sales of 289 million yuan, 209 million yuan, and 169 million yuan respectively [5] Group 4: Company Highlights - Limin Co. reported a revenue of 1.211 billion yuan for Q1 2025, a year-on-year increase of 22.28%, with a net profit of 108 million yuan, marking a turnaround due to strong demand and price increases [10] - Aonlikang focuses on innovative drugs and generics, with a recent trading volume of 1.393 billion yuan and a net institutional purchase of 235 million yuan [11][15] - Chutianlong is actively developing a digital RMB smart contract platform, collaborating with multiple organizations to provide integrated solutions for various scenarios [18]

Core Viewpoint - Lianhua Technology (联化科技) experienced a significant stock price drop after a period of rapid increase, with a trading halt on June 11, 2023, closing at 13.32 yuan, following a peak increase of over 124% in the previous weeks [2][4]. Group 1: Stock Performance - On June 11, Lianhua Technology's stock hit the daily limit down, with a trading volume of 22.09 million hands and a transaction value of 3.08 billion yuan, including over 650,000 hands traded at the limit down price [2]. - From May 28 to June 10, the stock recorded six limit up days out of nine trading days, indicating high volatility and investor interest [2]. Group 2: Company Operations - Lianhua Technology confirmed that there were no undisclosed significant matters affecting stock trading, and its production and operational conditions remain normal [2][4]. - The company operates under a CDMO model for producing advanced intermediates for chlorantraniliprole, maintaining a long-term partnership with its client, but has not received any notifications regarding increased product demand [4]. Group 3: Financial Performance - For the fiscal years 2022 to 2024, Lianhua Technology reported revenues of 7.865 billion yuan, 6.442 billion yuan, and 5.677 billion yuan, with net profits of 697 million yuan, -465 million yuan, and 103 million yuan respectively [4]. - In Q1 2025, the company achieved a revenue of 1.51 billion yuan, a year-on-year increase of 3.02%, and a net profit of 49.72 million yuan, reflecting a substantial year-on-year growth of 1747.04% [6]. Group 4: Business Segments - The improvement in Q1 2025 was attributed to the recovery of gross margins in the plant protection segment and steady development in the pharmaceutical segment, along with gains from foreign exchange [7]. - Despite the positive performance, the company faces challenges in the competitive new energy market, which has put pressure on its financial results due to depreciation of fixed assets [7].